AbbVie to Acquire Apogee Therapeutics in $10.9B Deal
AbbVie Inc. (ABBV) announced it will acquire Apogee Therapeutics Inc. (APGE) for $10.9 billion in cash, representing a 49% premium. Apogee shares surged to an all-time high following the announcement.
Key Numbers
AbbVie Inc. (NYSE: ABBV) announced the acquisition of Apogee Therapeutics Inc. (NASDAQ: APGE) in an all-cash deal valued at approximately $10.9 billion, representing a 49% premium over Apogee's last closing price. Apogee shares soared to an all-time high on Monday as investors rushed in following the announcement.
Deal Details
| Item | Value |
|---|---|
| Total Consideration | $10.9 billion in cash |
| Premium | 49% over last close |
| Payment Method | All cash |
| Expected Closing | Not yet announced |
Rationale
AbbVie aims to bolster its respiratory and immunology pipeline through this acquisition. Apogee focuses on developing therapies for inflammatory and autoimmune diseases. The deal aligns with AbbVie's strategy to diversify revenue streams following the Humira patent expiration.
Regulatory Hurdles
The transaction is expected to undergo regulatory review by the FTC and SEC. No major antitrust concerns have been flagged yet, but the deal's size may attract scrutiny.
Impact on Stocks
Apogee (APGE) surged over 49% to a record high, while AbbVie (ABBV) traded relatively flat. Analysts view the deal as positive for AbbVie long-term but note potential short-term cash flow pressure.
Frequently Asked Questions
Found this useful? Share it